Top Markets
#1 MowCat MowCat +775.59%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.18%
#3 Akedo Akedo +43.02%
#4 Magma Finance Magma Finance +42.54%
#5 SIXSEVEN SIXSEVEN +28.89%
#6 MarsCoin MarsCoin +27.75%
#7 DeXe DeXe +27.23%
#8 Cortex Cortex +25.74%
#9 Staked ZIG Staked ZIG +16.36%
#10 Zignaly Zignaly +16.25%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Seaport Therapeutics, Inc. Common Stock Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

SPTX
Rank in Stocks #8294
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise... Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Share Price
$24.37
Market Cap
$1.30B
Change (1 day)
-7.16%
Change (1 year)
-
Country
US
Trade Seaport Therapeutics, Inc. Common Stock (SPTX)

Category

Healthcare
Revenue for Seaport Therapeutics, Inc. Common Stock (SPTX)
Revenue in Aug 2026 TTM: 0
According to Seaport Therapeutics, Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Seaport Therapeutics, Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH